- Q4
highlights include $15 million equity line, CancerQuest 2020 initiative
- POAI
revenues for FY 2019 total $1.4 million, primarily driven through
sale of proprietary STREAMWAY units
- Predictive
Oncology will continue to be pioneer in fields of biomarker
discovery, precision therapies
Predictive Oncology Inc. (NASDAQ: POAI), a knowledge-driven
company focused on applying its cutting-edge technology to cancer research,
released its financial report for fiscal year 2019, ending December 31, 2019.
The report also identified fourth-quarter highlights for the company (http://ibn.fm/CRxo2).
Noting that 2019 “was not without its challenges for the
entire healthcare technology industry,” POAI CFO Bob Myers observed that
Predictive Oncology “continued to execute on our business model, making a
synergistic acquisition and shoring up our balance sheet via a new $15 million equity
line from Oasis Capital. Our STREAMWAY(TM) line has maintained strong
disposable product sales and we continue to sell the STREAMWAY System.”
In its announcement, POIA outlined several key milestones
reached by the company during the fourth quarter, including securing a $15
million equity line with Oasis Capital and launching its CancerQuest
2020 initiative with ovarian cancer as the initial target. Other highlights
include subsidiary Helomics sequencing tumor cases in partnership
with UPMC Magee Women’s Hospital and subsidiary Skyline Medical completing its
largest STREAMWAY System order to a single hospital in company history.
Regarding the company’s financial numbers, the report noted
revenues for FY 2019 were $1.4 million, steady year over year when
compared to FY 2018, which was also $1.4 million. Revenues were primarily
driven through the sale of Predictive Oncology’s proprietary STREAMWAY units,
with 43 units sold in 2019. The company reported that gross margins remained
strong, declining slightly to 62% in 2019 from 71% in 2018; much of that
decline was tied to the increase in costs following the consolidation of the Helomics acquisition
in April 2019.
The growing company’s report detailed losses consistent with
a company investing in its long-term future. Net losses for 2019
totaled $19.7 million versus $10.1 million in 2018. General
and administrative expenses rose an estimated 111% to nearly $9.8
million in 2019 as a result of extraneous expenses and initial costs
related to the Helomics merger. Operational expenses also rose
to $3 million, compared to $1.8 million in 2018. Net loss in 2019
reflected impairment charges of $8.1 million on goodwill related to
the Helomics merger and $800,000 on intangibles.
In addition, Predictive Oncology saw a gain of $6.1
million as a result of the revaluation of the equity method investment
recorded following the initial 25% purchase of Helomics and after the
merger and consolidation of Helomics. Predictive Oncology also
incurred additional expenses of $4 million in 2019, primarily due to
an increase in interest expense, payment penalties, amortization of original
issue discounts and a loss on debt extinguishment related to notes payable.
“We continue to be very excited about the revenue and
monetization prospects for our precision medicine business, which will allow us
to be at the forefront of developing the artificial Intelligence (AI)-driven
predictive models of cancer, as well as our revolutionary STREAMWAY clinical
waste disposal products,” said POAI director and CEO Dr. Carl Schwartz.
“We will continue to execute upon our comprehensive strategy to deliver
long-term profitable growth and innovation while concentrating our efforts and
resources on our recently acquired Helomics business.
“Building on the successes in 2019, we have recently
announced the launch of our CancerQuest 2020 initiative, and we expect
Helomics’ first AI-driven predictive model of ovarian cancer to be ready for
initial commercialization in revenue generating projects with Pharma in
Q2-2020,” he continued. “Furthermore, we have signed a letter of intent to
acquire Quantitative Medicine, a biomedical analytics and computational biology
company with a unique machine learning (ML) framework that will be integrated
in with our Helomics business. Against this backdrop, we believe
that Predictive Oncology will be a leader in the application of AI
and ML to both the use of and search for new precision therapies.”
POAI is bringing precision medicine, or tailored
medical treatment using the individual characteristics of each patient, to the
treatment of cancer. Through the company’s Helomics division, the company
leverages its unique, clinically validated patient derived (PDx) smart tumor
profiling platform to provide oncologists with a road map to help individualize
therapy. In addition, the company is leveraging artificial intelligence and its
proprietary database of over 150,000 cancer cases tumors to build
AI-driven models of tumor drug repose to improve outcomes for the patients of
today and tomorrow.
For more information, visit the company’s website at www.Predictive-Oncology.com
NOTE TO INVESTORS: The latest news and updates
relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given
situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
